The Client on Isotretinoin Who Did Not Disclose
Three days after a course of six microneedling sessions with a 1.5 mm depth, a 27-year-old client mentions in passing that she has been taking oral isotretinoin 40 mg daily for the past four months, prescribed by a dermatologist. She says she did not think it was relevant because "it's just a vitamin A tablet". Her cheeks show persistent erythema and a small area of delayed healing at the last treatment site. She has two sessions left in her package and wants to book the next one for next week. She is otherwise well and has no other medical history.
1. Assess the clinical significance of the undisclosed isotretinoin and the findings on her cheeks, and state your immediate management.
Read the worked answer
Oral isotretinoin is a systemic retinoid that reduces sebum production, thins the epidermis and impairs barrier function and wound healing, and it can increase photosensitivity. These effects persist for a period after the last dose, which is why many practitioners apply a conservative waiting period, commonly cited as around six months, before resuming treatments that breach the skin such as microneedling or deeper peels. Microneedling at 1.5 mm creates thousands of controlled wounds, and on retinoid-compromised skin this raises the risk of delayed healing, prolonged erythema, infection, scarring and dyschromia.
The findings support concern: persistent erythema and a site of delayed healing are exactly the impaired-recovery pattern expected. They could also reflect low-grade infection or a contact reaction, so I would not assume one cause. Immediate management: do not perform further microneedling. Assess the area gently for warmth, swelling, discharge or increasing tenderness, and if any are present, refer promptly to her GP or dermatologist. Otherwise advise gentle cleansing, a bland barrier moisturiser, strict SPF 50 and avoidance of actives, exfoliation and heat, with review in one to two weeks. Contact her prescriber with consent to confirm the regimen and any guidance on skin procedures. Suspend the remaining sessions and explain why.
2. Address the consent and communication failure, and set out how the remaining package and future treatment should be handled.
Read the worked answer
The root problem is a disclosure failure at consultation. My intake process must capture medications, including prescribed ones the client may not connect to skin, and I should ask specifically about retinoids, antibiotics, anticoagulants and hormonal treatments rather than relying on an open question. I would review the intake form and consultation script to close that gap, and ask about changes at every appointment.
In the conversation with her, I avoid blame. She genuinely did not know, and my job is to make the reason clear: isotretinoin affects healing across the whole body, not just the face, so it changes which treatments are safe. I explain the waiting period, that it is a precaution based on impaired healing rather than a certainty of harm, and that her current redness and slow healing make caution clearly warranted. I acknowledge my own process gap in not drawing out the medication, which models honesty and reduces defensiveness.
Package handling: the remaining two sessions are suspended, not forfeited, and held as a credit until her prescriber confirms she has finished the course and an appropriate interval has passed. I put this in writing. Future treatment is conditional on medical clearance, a fresh consultation, a patch test and a reduced-intensity reintroduction, with a lower depth first and careful review. I document the disclosure, the findings, the suspension, the prescriber contact, the advice given and the revised agreement, and I record the intake process change in the clinic's quality records.